Last Patient Enrolled in the Phase 2 Trial with Transgene's TG4010 + Nivolumab + Chemotherapy for the First-Line Treatment of Advanced Lung Cancer (NSCLC) - BioSpace

Last Patient Enrolled in the Phase 2 Trial with Transgene's TG4010 + Nivolumab + Chemotherapy for the First-Line Treatment of Advanced Lung Cancer (NSCLC)  BioSpace

STRASBOURG, France--(BUSINESS WIRE)-- Regulatory News: Transgene (Paris:TNG), a biotech company that designs and develops virus-based ...